Abstract
In the last two decades or so the intramuscular administration of botulinum toxin type A, and more recently type B, has become an established first line treatment of many neurological and other medical disorders. So far, the toxin has been used mainly by experienced researchers and clinicians with extensive knowledge of its mode of action and potential adverse effects. However, in the foreseeable future it is likely that this treatment will be provided by more medical practitioners and in different clinical settings, especially as the range of its clinical indications increases. Botulinum toxin, in therapeutic doses, is a remarkably safe drug with relatively few adverse effects. The commonest adverse effects are muscle weakness, fatigue, flu-like symptoms, a dry mouth, dizziness and a skin rash. Nonetheless, serious adverse events may occur, albeit rarely, and it is imperative that prescribers of this treatment are thoroughly familiar with its potential risks. The purpose of this article is to review the possible adverse effects of botulinum toxin intramuscular injections, to describe the factors that might predispose to them and to summarise the strategies for their prevention and treatment.
Keywords: Botulinum toxin., adverse events, drug safety
Current Drug Safety
Title: The Possible Adverse Effects of Intramuscular Botulinum Toxin Injections and their Management
Volume: 1 Issue: 3
Author(s): A. Magid O. Bakheit
Affiliation:
Keywords: Botulinum toxin., adverse events, drug safety
Abstract: In the last two decades or so the intramuscular administration of botulinum toxin type A, and more recently type B, has become an established first line treatment of many neurological and other medical disorders. So far, the toxin has been used mainly by experienced researchers and clinicians with extensive knowledge of its mode of action and potential adverse effects. However, in the foreseeable future it is likely that this treatment will be provided by more medical practitioners and in different clinical settings, especially as the range of its clinical indications increases. Botulinum toxin, in therapeutic doses, is a remarkably safe drug with relatively few adverse effects. The commonest adverse effects are muscle weakness, fatigue, flu-like symptoms, a dry mouth, dizziness and a skin rash. Nonetheless, serious adverse events may occur, albeit rarely, and it is imperative that prescribers of this treatment are thoroughly familiar with its potential risks. The purpose of this article is to review the possible adverse effects of botulinum toxin intramuscular injections, to describe the factors that might predispose to them and to summarise the strategies for their prevention and treatment.
Export Options
About this article
Cite this article as:
Bakheit O. A. Magid, The Possible Adverse Effects of Intramuscular Botulinum Toxin Injections and their Management, Current Drug Safety 2006; 1 (3) . https://dx.doi.org/10.2174/157488606777934431
DOI https://dx.doi.org/10.2174/157488606777934431 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Fluorescein Fluorescence Use in the Management of Intracranial Neoplastic and Vascular Lesions: A Review and Report of a New Technique
Current Drug Discovery Technologies Biofilm Inhibition of Spoilage Bacteria by Argentinean Fruit Juices with Antihypertensive Activity
Current Pharmaceutical Biotechnology Safety and Efficacy of Melatonin in Pediatric Migraine Prophylaxis
Current Drug Safety Levosimendan: A Novel Agent in Heart Failure
Recent Patents on Cardiovascular Drug Discovery Induction of Cytochrome P450 3A by the Ginkgo biloba Extract and Bilobalides in Human and Rat Primary Hepatocytes
Drug Metabolism Letters Intra-arterial Instillation of a Nociceptive Agent Modulates Cardiorespiratory Parameters Involving 5-HT3 and TRPV1 Receptors in Anesthetized Rats
Cardiovascular & Hematological Disorders-Drug Targets Peptides as Carrier for Tumor Diagnosis and Treatment
Current Medicinal Chemistry - Anti-Cancer Agents Vascularization of Engineered Tissues: Approaches to Promote Angiogenesis in Biomaterials
Current Topics in Medicinal Chemistry A Systematic Review of Randomized Controlled Trials Examining the Nephroprotective Properties of Antihypertensive Medications
Current Hypertension Reviews Binary Actin-ADP-Ribosylating Toxins and their Use as Molecular Trojan Horses for Drug Delivery into Eukaryotic Cells
Current Medicinal Chemistry Pharmacological Management of Type 2 Diabetes Mellitus: An Update
Current Diabetes Reviews Clinical and Molecular Perspectives of Monogenic Hypertension
Current Hypertension Reviews Spontaneous Coronary Artery Dissection: Does Being Unemployed Matter? Insights from the GSCAD Registry
Current Cardiology Reviews Ranolazine : Effects on Ischemic Heart
Recent Patents on Cardiovascular Drug Discovery Ivabradine: The Hope for a Good Treatment of Ischemic Heart Disease
Current Medicinal Chemistry In-hospital Falls in Older Patients: The Risk Factors and The Role of Hyponatraemia
Current Aging Science Renal Blood Flow Dynamics in Inbred Rat Strains Provides Insight into Autoregulation
Current Vascular Pharmacology Endothelin-Converting Enzyme Inhibitors
Current Enzyme Inhibition New Perspectives on Acetaminophen
Current Cardiology Reviews Chest Pain in Children
Current Pediatric Reviews